Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. by Elliott, M, Maini, R, Feldmann, M, Kalden, JR, Antoni, C, Smolen, J, Leeb, B, Breedveld, F, Macfarlane, J, Bijl, H

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. by Maini, R, Breedveld, F, Kalden, JR, Smolen, J, Davis, D, Macfarlane, J, Antoni, C, Leeb, B, Elliott, M, Woody, J, Schaible, T, Feldmann, M

Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. by Charles, P, Elliott, M, Davis, D, Potter, A, Kalden, JR, Antoni, C, Breedveld, F, Smolen, J, Eberl, G, deWoody, K, Feldmann, M, Maini, R

Infliximab and methotrexate in the treatment of rheumatoid arthritis by Lipsky, P, Van Der Heijde, D, St Clair, E, Furst, D, Breedveld, F, Kalden, JR, Smolen, J, Weisman, M, Emery, P, Feldmann, M, Harriman, G, Maini, R

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. by Lipsky, P, van der Heijde, D, St Clair, E, Furst, D, Breedveld, F, Kalden, JR, Smolen, J, Weisman, M, Emery, P, Feldmann, M, Harriman, G, Maini, R

Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis (May 2000). by Furst, D, Breedveld, F, Burmester, G, Crofford, J, Emery, P, Feldmann, M, Kalden, JR, Kavanaugh, A, Keystone, E, Klareskog, L, Lipsky, P, Maini, R, Russell, A, Scott, D, Smolen, J, Van de Putte, L, Visher, T, Weisman, M